CONGRESS | #cGvHD2026 | ORAL PRESENTATION
Steven Pavletic provides an update on belumosudil 5 years after its approval in #cGvHD. He reviews the ROCKstar trial data that supported regulatory approval, along with findings from the ROCKstar companion study demonstrating tissue-level responses to belumosudil, including reduced collagen, T cells, and IL-17–producing cells in the oral buccal mucosa. He also discusses combination strategies involving belumosudil and outlines future directions such as moving the agent into earlier lines of therapy.
Follow our live feed for more updates: https://t.co/Z8MqTc6beZ
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedNews #MedEd @StevenPavletic
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: https://t.co/tvPYrBCWj8
A Review in @NatRevClinOncol discusses the promises and limitations of liquid biopsy-based tests for multi-cancer early detection. https://t.co/ENgYJvjGkJ 🔒
Staphylococcus aureus bacteremia has a case fatality rate of 15% to 30% and causes 300 000 deaths per year worldwide.
This Review discusses management of S aureus bacteremia.
https://t.co/BYBHl4uBeI
In case you missed it:
Is sirolimus an alternative option to tacrolimus for GvHD prophylaxis following haploidentical allo-HCT?
🔎Find out more in our visual abstract: https://t.co/tutuRdogKN
#GvHDsm
لعملاء #مياه_ايفال خلك قريب ..
يمكن تكون أنت الفائز! 🤩
سحب يومي على جهاز ايفون 15 برو 📱
كل اللي عليك تتابع حسابنا وتفعّل التنبيهات
وفالك الفوز في شهر الخير
#مسابقة_ايفال_الرمضانية 🌙
Today an FDA advisory committee considers a gene editing treatment for sickle cell disease.
This short explains the principles of DNA editing with #CRISPR-Cas9 and the rationale for its use.
Watch the video in full: https://t.co/gUNwzj4dkY
Study: Individuals with severe #sicklecell disease are highly interested in new, potentially curative gene therapy treatments and willing to accept associated risks for a chance at a cure.
Read more: https://t.co/LDA2LuEDj3 @BloodAdvances#genetherapy@CayenneWellness@DukeU